PURPOSE: MRL/MpJ mice of substrains MRL/MpJ-fas(+)/fas(+) (MRL/+) and MRL/MpJ-fas(lpr)/fas(lpr) (MRL/lpr) spontaneously develop autoimmune dacryoadenitis and sialadenitis and are a model for the human disorder Sjögren syndrome. The dacryoadenitis in both substrains appears to be Th2 in nature, with little IFN-gamma and substantial IL-4 at the site of lacrimal gland inflammation. METHODS: MRL/MpJ mice with a defective IL-4 gene-both MRL/+-IL-4(tm)/IL-4(tm) (MRL/+/IL-4(tm)) and MRL/lpr-IL-4(tm)/IL-4(tm) (MRL/lpr-IL-4(tm))-that resulted in a loss of IL-4 production were bred and evaluated for dacryoadenitis. RESULTS: MRL/+/IL-4(tm) and MRL/lpr/IL-4(tm) mice developed dacryoadenitis of similar onset, appearance, and severity as found in MRL/MpJ mice with an intact IL-4 gene. Immunohistochemistry examination revealed a substantially greater number of inflammatory cells staining for IFN-gamma than for IL-13 in the dacryoadenitis of IL-4-deficient MRL/MpJ mice (MRL/+/IL-4(tm), 66% vs. 0.8%, P = 0.001; MRL/lpr/IL-4(tm), 67% vs. 1.2%, P = 0.002). Real-time PCR demonstrated greater amounts of IFN-gamma than IL-13 mRNA relative transcripts in lacrimal glands of MRL/lpr/IL-4(tm) mice (mean difference, 28.6; P = 0.035). Greater CD86 (B7-2) than CD80 (B7-1) expression was present in MRL/+/IL-4(tm) mice (11% vs. 3%, P = 0.003) and MRL/lpr/IL-4(tm) mice (10% vs. 3%, P = 0.002). CONCLUSIONS: These results suggest that a Th2 autoimmune process can be converted to a Th1 process in the absence of IL-4.
PURPOSE: MRL/MpJ mice of substrains MRL/MpJ-fas(+)/fas(+) (MRL/+) and MRL/MpJ-fas(lpr)/fas(lpr) (MRL/lpr) spontaneously develop autoimmune dacryoadenitis and sialadenitis and are a model for the human disorder Sjögren syndrome. The dacryoadenitis in both substrains appears to be Th2 in nature, with little IFN-gamma and substantial IL-4 at the site of lacrimal gland inflammation. METHODS: MRL/MpJ mice with a defective IL-4 gene-both MRL/+-IL-4(tm)/IL-4(tm) (MRL/+/IL-4(tm)) and MRL/lpr-IL-4(tm)/IL-4(tm) (MRL/lpr-IL-4(tm))-that resulted in a loss of IL-4 production were bred and evaluated for dacryoadenitis. RESULTS: MRL/+/IL-4(tm) and MRL/lpr/IL-4(tm)mice developed dacryoadenitis of similar onset, appearance, and severity as found in MRL/MpJ mice with an intact IL-4 gene. Immunohistochemistry examination revealed a substantially greater number of inflammatory cells staining for IFN-gamma than for IL-13 in the dacryoadenitis of IL-4-deficient MRL/MpJ mice (MRL/+/IL-4(tm), 66% vs. 0.8%, P = 0.001; MRL/lpr/IL-4(tm), 67% vs. 1.2%, P = 0.002). Real-time PCR demonstrated greater amounts of IFN-gamma than IL-13 mRNA relative transcripts in lacrimal glands of MRL/lpr/IL-4(tm)mice (mean difference, 28.6; P = 0.035). Greater CD86 (B7-2) than CD80 (B7-1) expression was present in MRL/+/IL-4(tm)mice (11% vs. 3%, P = 0.003) and MRL/lpr/IL-4(tm)mice (10% vs. 3%, P = 0.002). CONCLUSIONS: These results suggest that a Th2 autoimmune process can be converted to a Th1 process in the absence of IL-4.
Authors: I G Luzina; R H Knitzer; S P Atamas; W C Gause; J C Papadimitriou; M B Sztein; C E Storrer; B S Handwerger Journal: Arthritis Rheum Date: 1999-03
Authors: D Serebrisky; A A Teper; C K Huang; S Y Lee; T F Zhang; B H Schofield; M Kattan; H A Sampson; X M Li Journal: J Immunol Date: 2000-11-15 Impact factor: 5.422
Authors: Douglas A Jabs; Hérvé C Gérard; Yuewang Wei; Adam L Campbell; Alan P Hudson; Esen Karamursel Akpek; Bella Lee; Robert A Prendergast; Judith A Whittum-Hudson Journal: Invest Ophthalmol Vis Sci Date: 2004-07 Impact factor: 4.799
Authors: Esen Karamursel Akpek; Douglas A Jabs; Hervé C Gérard; Robert A Prendergast; Alan P Hudson; Bella Lee; Judith A Whittum-Hudson Journal: Invest Ophthalmol Vis Sci Date: 2004-01 Impact factor: 4.799
Authors: C S De Paiva; J K Raince; A J McClellan; K P Shanmugam; S B Pangelinan; E A Volpe; R M Corrales; W J Farley; D B Corry; D-Q Li; S C Pflugfelder Journal: Mucosal Immunol Date: 2010-12-22 Impact factor: 7.313
Authors: In-Cheon You; Fang Bian; Eugene A Volpe; Cintia S de Paiva; Stephen C Pflugfelder Journal: Invest Ophthalmol Vis Sci Date: 2015-04 Impact factor: 4.799
Authors: Flavia S A Pelegrino; Eugene A Volpe; Niral B Gandhi; De-Quan Li; Stephen C Pflugfelder; Cintia S de Paiva Journal: Arthritis Res Ther Date: 2012-11-01 Impact factor: 5.156